Biopharma is entering a new kind of “patent cliff”—not just for drugs, but for talent.
Here’s the uncomfortable truth: the race to build the next pipeline doesn’t start when a company’s R&D headcount is already stretched. It starts earlier—when rec…

Stop Overstocking Branded Drugs—Or Pay for It Twice
Branded drug inventory risk isn’t just a finance problem. It’s a timing problem.
When wholesalers overstock branded products, the cost shows up in multiple places at once: cash tied up in slow-moving …

Big Pharma doesn’t just “restructure” when a patent cliff hits—it often rehearses the shift long before anyone outside the building notices.
Here’s the hidden hiring signal many leaders miss: patent cliff events don’t only forecast revenue pressure. Th…

Biosimilar switching isn’t a procurement problem—it’s a patent strategy problem.
If you’re planning a biosimilar switch, you’re probably thinking about price, contracting, and formulary timing. Those matter. But the real swing factor is often hiding in…

Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
A decade ago, “repurposed” drugs were often framed as a public-health win: take an existing molecule, find a new indication, and deliver faster access than starting fr…

Pharma hiring is broken in a very specific way: we keep asking for “the best scientists,” but we rarely measure where scientific impact actually shows up.
Most recruiters still rely on titles, prestige signals, and keyword-matching on resumes. That app…

Pharma has a familiar playbook: take an old drug, reframe it as “new,” and price it like it’s never been seen before.
That’s the tension at the heart of “Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines.” The article…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule may sound like bureaucracy. But patent filings are telling a different story.
In the world of pharmaceuticals, the loudest signals aren’t always press releases—they’re paperwork.
A recent DrugPatentWatch analysis highlights …

Europe’s divisional patent game: how “final decisions” get delayed—and generics pay the price
Europe is supposed to be the place where patent law balances innovation with access. But a growing body of litigation strategy suggests something else: the sy…